A study, published in Annals of Internal Medicine, sought to identify novel protein biomarkers in stool that would detect colorectal cancer and advanced adenomas at a greater rate than hemoglobin.

cf-bDNA testing can reduce CRC incidence and mortality but is less effective and more costly than colonoscopy and FIT. The test may increase screening participation among those who avoid traditional ...